Company News
Sun Pharma Partner Philogen Resubmits Nidlegy MAA to EMA
Sun Pharma's partner Philogen resubmitted Nidlegy Marketing Authorization Application to EMA for neoadjuvant melanoma treatment.
Updated submission includes 33-month follow-up data from Phase III PIVO
